Corbus Pharmaceuticals Reports 5% Weight Loss in Phase 1b Obesity Trial
Corbus Pharmaceuticals' oral obesity drug CRB-913 achieved 5.0% weight loss in a 12-week Phase 1b study, with the company now planning regulatory…
Corbus Pharmaceuticals' oral obesity drug CRB-913 achieved 5.0% weight loss in a 12-week Phase 1b study, with the company now planning regulatory…
Ascletis Pharma advances its obesity pipeline with an FDA IND submission for ASC30_39 FDC, an oral combination therapy leveraging the company's proprietary…
Survodutide met its primary cardiovascular safety endpoint in the Phase 3 SYNCHRONIZE-CVOT trial, showing significant cardiometabolic benefits including weight loss of up…
Eli Lilly shares see potential upside as Phase 3 trials for retatrutide show substantial efficacy in treating knee osteoarthritis and obesity, with…
Eli Lilly's EloraTZP trial results show a 23.3% average weight loss, signaling a potential new benchmark in the company's obesity and type…